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Systematic reviewers are increasingly trying to obtain regulatory clinical study reports (CSRs) to correct for
publication bias. For instance, our organization, the Institute for Quality and Efficiency in Health Care, routinely asks
drug manufacturers to provide full CSRs of studies considered in health technology assessments. However, since
cooperation is voluntary, CSRs are available only for a subset of studies analysed. In the case of the inhaled insulin
Exubera, the manufacturer refused to cooperate and in 2007 we asked the European Medicines Agency (EMA) to
provide the relevant CSRs, but EMA denied access. Other researchers have reported similar experiences.
In 2010 EMA introduced a new policy on access to regulatory documents, including CSRs, and has also undertaken
further steps. The new policy has already borne fruit: in 2011, by providing additional sections of relevant CSRs,
EMA made an important contribution to a review of oseltamivir (Tamiflu).
Unfortunately, speedy implementation of the new policy may be endangered. We define a CSR following the
International Conference on Harmonisation (ICH) E3 guideline. Although this guideline requires individual patient
data listings, it does not necessarily require that these listings be made available in a computer-readable format, as
proposed by some regulators from EMA and other agencies. However, access to raw data in a computer-readable
format poses additional problems; merging this issue with that of access to CSRs could hamper the relatively
simple implementation of the EMA policy. Moreover, EMA plans to release CSRs only on request; we suggest
making these documents routinely available on the EMA website.
Public access to regulatory data also carries potential risks. In our view, the issue of patient confidentiality has been
largely resolved by current European legislation. The risk of other problems, such as conflicts of interest (CoIs) of
independent researchers or quality issues can be reduced by transparency measures, such as the implementation of
processes to evaluate CoIs and the publication of methods and protocols.
In conclusion, regulatory data are an indispensable source for systematic reviews. Because of EMA’s policy change, a
milestone for data transparency in clinical research is within reach; let’s hope it is not unnecessarily delayed.
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The effects of publication bias, i.e. the tendency to over-
estimate benefits and underestimate harms of health care
interventions, are well known [1,2]. Some researchers
from health technology assessment (HTA) agencies and
other authors of systematic reviews therefore try to obtain
full clinical study reports (CSRs) of all relevant studies in
order to produce unbiased assessments. For example, our
organization, the Institute for Quality and Efficiency in* Correspondence: beate.wieseler@iqwig.de
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reproduction in any medium, provided the orHealth Care (IQWiG), which prepares HTA reports for
the German statutory health care system, routinely asks
the drug manufacturer to provide an overview of spon-
sored published and unpublished studies on the drug of
interest. From this list we select the studies deemed rele-
vant to the assessment and ask the manufacturer to sub-
mit the full CSRs. However, since submission of study
overviews and CSRs by the manufacturer is voluntary,
these documents are available only for a subset of the
studies assessed (less than 40% [3]). For instance, in the
case of the inhaled insulin Exubera, the manufacturer
refused to cooperate and in March 2007 we thereforel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the relevant CSRs. However, EMA denied access, stating
that they needed the manufacturer’s consent to release the
documents. Similarly, a request to EMA by two research-
ers from the Nordic Cochrane Centre, Gøtzsche and
Jørgensen, to provide CSRs and protocols for two anti-
obesity drugs was initially rejected in August 2007 [4].
EMA gave several reasons for not releasing the docu-
ments, among others, the protection of commercial inter-
ests. After a struggle of more than 3 years, including a
complaint to the European ombudsman (who then pub-
licly criticized EMA’s behaviour), the data were finally pro-
vided in February 2011.
Main text
Non-inclusion of clinical study reports leads to biased
evidence syntheses
Previous research has shown that the non-inclusion of
CSRs in systematic reviews and HTAs results in an
incomplete evidence base and potentially biased conclu-
sions about the effects of an intervention [3,5,6]. In an
analysis of primary studies and corresponding docu-
ments (registry reports, CSRs, journal publications) from
16 HTAs of drugs conducted by IQWiG between 2006
and February 2011, we investigated to what extent these
three types of documents deliver sufficient information
for trial evaluation. The HTAs included 268 studies:
publications, CSRs and registry reports were available
for 192 (72%), 101 (38%), and 78 (29%) studies, respect-
ively. Reporting quality was highest in the 101 CSRs,
which overall provided complete information on 90%
(1086/1212) of 12 required items for study methods and
outcomes (e.g., reporting of randomization, allocation
concealment, the primary endpoint, and adverse events).
By contrast, registry reports and publications provided
complete information on only 51% (477/936) and 46%
(1052/2304) of items, respectively [3].
In 2009 IQWiG published an HTA report on reboxetine
and other antidepressants [7]. The manufacturer only
provided the relevant CSRs after an intense public debate.
The inclusion of unpublished data from these CSRs (add-
itional data on published studies as well as completely un-
published studies) called into question the previous
positive conclusions about the benefits and harms of
reboxetine based on published data alone. These data ac-
tually overestimated the benefits of reboxetine by up to
115% and 23% versus placebo and active comparators re-
spectively, and also underestimated harms [5].
A further example is the case of the neuraminidase
inhibitor oseltamivir (Tamiflu) experienced by Doshi,
Jefferson and other colleagues, who were the authors of a
Cochrane review on the drug. Claims concerning its
effectiveness in reducing important complications of influ-
enza were based on a meta-analysis of mostly unpublishedindustry-sponsored trials [8]. In September 2009, in an
attempt to verify these claims, the authors requested the
relevant data from the manufacturer, who at first unsuc-
cessfully tried to implement a confidentiality agreement,
and then provided data that were incomplete and insuffi-
cient to verify the methods and results of the unpublished
trials [8]. After further attempts to obtain the relevant
data, the manufacturer provided about 3200 pages of
CSRs in 2010. Further tens of thousands of pages were
provided by EMA in 2011 after a Freedom of Information
request. The authors concluded that this unpublished in-
formation had “turned our understanding of the drug’s
effects on its head” [6]. Among other things, the CSRs
provided information that allowed the authors to deter-
mine the total number of trials that might fit the system-
atic review inclusion criteria, to analyse serious adverse
events not mentioned in published papers, and to assess
the validity of published information. However, the evi-
dence on Tamiflu is still incomplete as the full set of CSRs
in the manufacturer’s possession has not been released [6].
First step to a solution: EMA changes its policy
As already indicated above, in 2010 EMA introduced a
new policy on access to clinical trial documents, includ-
ing the release of documents submitted as part of mar-
keting authorization applications (e.g. CSRs), after
procedures concerning a drug had been finalized [9].
The change in attitude by regulatory authorities has also
been echoed in a recent article by European regulators
from EMA and other agencies (Eichler et al.), who stated
that it was “neither desirable nor realistic to maintain
the status quo of limited availability of regulatory trials
data” [10].
EMA has also recently taken further steps to put the
new policy into practice by clarifying open issues raised
in a public consultation. The agency has published an
update of its policy document, as well as an accompany-
ing guidance document on the handling of commercially
confidential information and personal data [11,12].
Discussion
Differing definitions of clinical study reports
We define a CSR following the International Conference
on Harmonisation (ICH) E3 guideline [13]. According to
ICH E3, a CSR, in addition to containing the full proto-
col, a statistical analysis plan, and summarized efficacy
and safety data on all outcomes, also contains individual
patient data in the format of tabulations or listings, but
not necessarily in the format of an electronic database
ready for computer-based analysis. (This type of format
is only intended to be made available by sponsors on re-
quest but is not a regular component of the CSR [13]).
However, the above regulators extend this definition of a
CSR to include the full raw data set, which on the basis
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as an electronic database. It has long been proposed to
make raw data from clinical trials available for re-
analysis [14-17], and besides verifying the results of clin-
ical trials or testing additional hypotheses, access to such
data may also offer additional advantages, such as enab-
ling the development of innovative strategies for the
individualized management of patients [10].
Speedy implementation of EMA policy needed, not
complication
We acknowledge the potential advantages of analysing
raw data and that making both CSRs and raw data in a
computer-readable format publicly available in the near
future would be a huge step forward. We thus under-
stand the rationale for this proposal. However, compared
to public access to “conventional” CSRs, public access to
CSRs supplemented by raw data in a computer-readable
format would require additional measures, for example,
to prevent misuse in the form of selective reanalyses of
data by other researchers. We fear that the discussions
about these requirements and their implementation will
lead to long and unnecessary delays. In our opinion,
making full CSRs available and providing raw data in a
computer-readable format are two separate issues. Mer-
ging them would hamper the relatively simple (but
ground-breaking) implementation of the new EMA pol-
icy. Instead, the requirements for publishing such raw
data should be discussed in parallel.
A further point to consider is that EMA plans to
release CSRs only on request. We would suggest making
these documents routinely available on the EMA website
after marketing authorization. This could be done by in-
cluding a link to the CSRs of studies considered in the
authorization process and listed in the European Public
Assessment Reports (EPAR).
Risks and benefits of access to regulatory data
Patient confidentiality has been a major concern in the
discussion about making extended information (including
individual patient data) from clinical trials available. Since
CSRs also include individual patient data listings, in
principle, this issue not only applies to raw data in a
computer-readable format but also to CSRs. However, as
stated by EMA, “current European legislation requires pa-
tient information to be included in non-identifiable form
in the marketing authorization application submitted to
competent authorities” [12]. Given these requirements, it
seems unrealistic that data listings in a CSR would contain
patient-identifying information, although the risk might be
higher for raw data sets, where patient characteristics can
be re-arranged and combined electronically. As Eichler
et al. note, there might be exceptional cases (for example,
trials in “ultra-rare” diseases) where it could be difficult toensure patient confidentiality. In such cases, a simple pre-
liminary solution would be to split off individual patient
data listings before the release of CSRs. This would allow
discussion of measures to ensure patient confidentiality
without delaying the release of large parts of the informa-
tion on these trials.
Other potential problems, such as conflicts of interest
(CoIs) of “independent” researchers and the misuse of
public access to CSRs for personal or competitive pur-
poses probably cannot be fully avoided. However, this also
applies to systematic reviews based on journal publica-
tions. The risk of CoIs (and of quality deficits) in system-
atic reviews can be reduced by transparency measures. For
example, organizations such as IQWiG and the Cochrane
Collaboration publish their methods, protocols and
reports online and have also implemented processes to
evaluate CoIs of participating researchers [18,19]. It
should be noted here that commercial CoIs, including
data spinning and the withholding of study results, have
demonstrably caused substantial damage [2]. Previous
drug safety catastrophes, such as the cases of rofecoxib
(Vioxx) and class 1 antiarrhythmic agents, which harmed
tens of thousands of patients [4,20,21], highlight the need
for access to CSRs beyond regulatory agencies. In addition,
access to such documents could help avoid wasting public
funds, as exemplified in the case of Tamiflu, where in the
United States alone over a billion dollars were spent on
stockpiling a drug that “may be no better than aspirin” [6].
Overall, in our view the benefits of public access to CSRs
far outweigh the risks.
Conclusion
In conclusion, regulatory data in the form of CSRs are
an indispensable source for systematic reviews. The
debate between EMA, its stakeholder groups and inter-
ested parties on access to CSRs, including the issue of
the level and format of data to be provided, is still on-
going [22]. As a result of EMA’s policy change, a mile-
stone for data transparency in clinical research is within
our reach; let’s hope it is not unnecessarily delayed by an
insistence that raw data in a computer-readable format
be released together with CSRs.
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